Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian G. Sacher, Jayesh Desai, Luis Paz‐Ares et al.|New England Journal of Medicine|2023Cited by 307
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzmán Alonso, Se Hyun Kim et al.|Nature Medicine|2023Cited by 128
Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with <i>KRAS G12C</i> mutationJayesh Desai, Manish Patel, Sae‐Won Han et al.|Cancer Research|2023Cited by 10
Phase 1B Study of Mehd7945A (Mehd) Plus Cisplatin/Fluorouracil (Cis/5Fu) or Carboplatin/Paclitaxel (Carbo/Pac) for 1St-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (Rmscchn)Paul M. Clément, Antonio Jimeno, Jean‐Pascal Machiels et al.|Annals of Oncology|2014Cited by 3
Abstract CT022: Divarasib plus migoprotafib combination treatment in patients with <i>KRAS G12C</i>-positive non-small cell lung cancer (NSCLC)Jia Luo, Myung‐Ju Ahn, Adrian G. Sacher et al.|Cancer Research|2025Cited by 2